ANGIOEDEMA Clinical Trial
Official title:
International Registry of Isolated Angioedema
Angioedema is a disease characterized by the appearance of self-limiting edema that last 1-5 days and affect the subcutaneous tissue and/or gastrointestinal and oropharyngeal mucosa. In this last location edema can be lethal causing asphyxia, in all other cases full recovery is complete. Attacks can appear as part of the syndrome urticaria angioedema and can be of allergic origin. But there is a group of non-allergic angioedema that occur without hives and can be either hereditary or acquired. These angioedema are identified in some cases on the basis of etiology, in others are identified by the mediator and an overall classification of these forms of angioedema was published in 2014 as a result of a consent conference organized by the proponents of this registry. Being these forms of angioedema rare, there are not significative case studies inclusive of a high number of patients. This registry aims to collect in a single place a high number of subjects with recurring angioedema and without urticaria.
The Grenoble center is the registry coordinator at the national level. It will contract directly with the Cloud R Company and will be in charge of coordinating the associated centers. It will therefore send the necessary documents for the good execution of the study, will ask each center to respect the current French regulatory, will organize and finance the set-up of the register in the associated centers. The coordinating center will also centralize requests for data, publications or creation of additional eCRF pages of associated centers. It will be able to organize a national scientific committee every 6 months. It will thus be the link between the French centers, the scientific committee of the registry and the company Cloud R. The coordinating center will also be responsible for enter and reliability of patient data from it center, as well as the associated centers. Role of associated centers Associated Centers will be responsible for capturing and data reliability of their patients in eCRF, they will also create a personal account for each patient so that it can download the application "cloud R HAE carnet de suivi". Investigators referent patient will have validated at each visit or after contact with the patient crisis returned to the patient via it electronic diary. Associated Centers will keep informed twice a year the coordinator center of the state of inclusions in the register. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT00163839 -
The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema
|
N/A | |
Recruiting |
NCT04597944 -
Lanadelumab in Bradykinin Angioedema
|
||
Completed |
NCT00876369 -
Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema
|
||
Completed |
NCT02833675 -
Determination of Specific Biomarkers of Angioneurotic Crisis
|
N/A | |
Completed |
NCT06096077 -
Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department
|
||
Completed |
NCT00125541 -
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
|
Phase 2/Phase 3 | |
Completed |
NCT01371877 -
The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment
|
N/A | |
Completed |
NCT04206605 -
A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
|
Phase 3 | |
Unknown status |
NCT01036659 -
Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
|
Phase 2 | |
Recruiting |
NCT05578417 -
A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada
|
||
Recruiting |
NCT05936567 -
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
|
Phase 2 | |
Recruiting |
NCT04334031 -
Deployment o the Multidisciplinary Prospective Cohort Imminent
|
N/A | |
Completed |
NCT03240991 -
Study of Clinical, Biological Characteristics and Quality of Life of Patients With Hereditary or Acquired Non Drug-induced Bradykinin-mediated Angioedema, Monitored in Besançon's Partner Site Reference Center for Studies of Kinin-mediated Angioedema (CREAK)
|
||
Completed |
NCT01723072 -
Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy
|
Phase 3 | |
Completed |
NCT00385372 -
Significance of an Elimination and Provocation Diet in Patients With Chronic Urticaria
|
N/A | |
Completed |
NCT00004694 -
Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations
|
N/A | |
Not yet recruiting |
NCT06210698 -
Angioedema Biomarker Research Study
|
||
Terminated |
NCT04128371 -
Mepolizumab in Episodic Angioedema With Eosinophilia
|
Phase 2 | |
Completed |
NCT04444895 -
A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor
|
Phase 3 | |
Completed |
NCT00125151 -
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
|
Phase 3 |